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Abstract
Context—Cognitive impairment in late-life depression is a core feature of the illness.
Objective—to test whether donepezil + antidepressant is superior to placebo + antidepressant in
(1) improving cognitive performance and instrumental activities of daily living and (2) reducing
recurrences of depression over two years of maintenance treatment.
Design—Randomized, double-blind, placebo controlled maintenance trial.
Setting—university clinic
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Main Outcome Measures—global neuropsychological performance, cognitive instrumental
ADL, and recurrent depression.
Results—Donepezil + antidepressant temporarily improved global cognition (treatment by time
interaction F = 3.78, df = 2, 126, p = .03), but effect sizes were small (Cohen’s d = 0.27: group
difference at 1 year). A marginal benefit to cognitive instrumental ADL was also observed
(treatment by time interaction; F = 2.94; df = 2, 137, p = 0.06). The donepezil group was more
likely to experience recurrent major depression: 35% [95% CI: 24%, 46%] versus 19% [95% CI:
9%, 29%] (log rank chi squared = 3.97, p = .05); hazard ratio = 2.09 [95% CI: 1.00, 4.41]. Post-
hoc subgroup analyses showed that, of 57 participants with mild cognitive impairment, 3/30 on
donepezil (10%; 95% CI: 0, 21%) and 9/27 on placebo (33%; 95% CI: 16%, 51%) converted to
dementia over two years (Fisher exact p = 0.05). The MCI subgroup had a 44 percent recurrence
rate of major depression on donepezil verses 12% on placebo (LR=4.91, p=.03). The subgroup
with normal cognition (n = 73) showed no benefit on donepezil or increase in recurrence of major
depression.
Conclusion—Whether ChEI should be used as augmentation in the maintenance treatment of
late-life depression depends upon a careful weighing of risks and benefits in those with MCI. In
cognitively intact patients, donepezil appears to have no clear benefit for preventing progression to
MCI/dementia or recurrence of depression.
BACKGROUND
Cognitive impairment in late-life depression is a core feature of the illness, contributing to
disability and impaired quality of life. Even after remission, cognitive functions do not
improve to levels seen in non-depressed subjects 1-3. Moreover, cognitive and functional
impairment may progress. Depression is increasingly thought to be a possible risk factor for,
or a prodrome to, dementing illnesses 4, 5.
We report here the efficacy and safety of combining a cholinesterase inhibitor (ChEI) with
maintenance antidepressant pharmacotherapy over two years to improve global cognitive
performance and cognitive instrumental activities of daily living (C-IADL) in older, non-
demented adults with a recent major depressive episode. We chose ChEI therapy because of
evidence that it may: (a) prevent symptomatic progression of mild cognitive impairment
(MCI) 6, especially in subjects with depressive symptoms 7, (b) remediate cholinergic
deficits and enhance cerebral blood flow — potentially an effect relevant to the pathogenesis
of vascular dementia 8 and, perhaps, depression 9, and (c) modify amyloid precursor protein
metabolism and have neuroprotective effects 10. In addition, we chose donepezil because of
its potential efficacy in MCI 6, 7, pharmacokinetic properties allowing once daily dosing,
and generally good tolerability and safety data 11. RCTs comparing the FDA-approved
ChEIs in Alzheimer’s Disease suggest no major difference in therapeutic efficacy 12, 13.
One of the most consistent effects of ChEIs in Alzheimer’s Disease is the improvement of
neuropsychiatric symptoms such as apathy 14-16 (although not agitation) 17. Since executive
dysfunction may increase the risk of depression recurrence 18, it is possible that
enhancement of executive functioning by donepezil could also protect patients from
depression recurrence. At the same time, however, ChEIs may induce symptoms of
depression because of cholinergic hypersensitivity conferred by depression 19, 20.
Consistent with the proposed cholinergic role in the regulation of mood and affect is the
recent finding that scopolamine produces a rapid and robust antidepressant response,
possibly via modulation of N-methyl-D-aspartate receptor function21.We expected that a
depressogenic effect of donepezil would be less likely than positive behavioral effects in
participants already in remission from their depressive episodes and on maintenance
antidepressant pharmacotherapy.
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Our primary hypotheses were that donepezil + antidepressant in older non-demented adults
with a recent major depressive episode would be superior to placebo + antidepressant in (1)
improving global cognitive performance and cognitive IADLs over a two-year period; and
(2) reducing recurrences of major depression. We did not have an a priori hypothesis that
donepezil would reduce rates of conversion to dementia in depressed subjects with MCI, in
light of the Cochran review conclusions of donepezil’s modest effects and side effect burden
in MCI.13
METHODS
Overview
Participants received two phases of treatment: (a) 12-16 weeks of open antidepressant
pharmacotherapy with supportive depression care management to bring about response and
thereby to establish eligibility for (b) the randomized, placebo-controlled maintenance phase
of treatment (2 years). Following antidepressant response during the first phase, participants
had baseline neuropsychological, cognitive IADL assessment, and adjudication of cognitive
status (normal, MCI, dementia) by the University of Pittsburgh Alzheimer’s Disease
Research Center (ADRC). Subjects were then randomized and had repeated
neuropsychological and IADL assessment 12 and 24 months later. The protocol was
approved by the Institutional Review Board of the University of Pittsburgh, and all subjects
provided written informed consent.
Depressed Participants
We screened and recruited 299 adults aged 65 and older from primary care practices, mental
health clinics, other federally sponsored clinical research projects, and advertisements
(Figure 1). 220 qualified for participation and signed consent. 158 responded to open
antidepressant treatment and completed assessment for the randomized controlled trial. 130
eligible subjects agreed to randomization. The first depressed subject entered in 4/04, and
the last exited in 9/09.
To qualify, subjects needed to be: (a) 65 or older, (b) in a non-bipolar, non-psychotic major
depressive episode 22, (c) with a score of≥15 on the 17-item Hamilton Rating Scale for
Depression (HAM-D) 23, and (d) either cognitively normal or with MCI. We included
cognitively normal subjects because major depressive disorder in later life frequently heralds
the onset of MCI (25%-30% within 12 months) and subsequent dementia. 3, 24, 25 The
question addressed is whether donepezil protects cognitively normal patients from
developing MCI. We included subjects with MCI to test for cognitive improvement on
donepezil. We report both primary analyses of the aggregate group of all participants (n =
130), as well as post-hoc analyses of the two subgroups who were either cognitively normal
(n = 73) or who were adjudicated to have Mild Cognitive Impairment (n = 57) at the start of
maintenance treatment. Participants with dementia were excluded, as were those with
substance use disorders. Informant information was used in assessing subjects’ behavior and
cognitive functioning. In general, subjects had mildly to moderately severe major depression
and could be safely treated as outpatients.
The ADRC Consensus Conference (co-investigators OL and STD) utilized post-depression
remission neuropsychological data, clinical history, MRI data, and PASS data 26
(Performance Assessment of Self-Care Skills). The following diagnoses were made
according to National Alzheimer Coordinating Center criteria 27: no cognitive disorder,
MCI amnestic-single domain, MCI amnestic-multiple domain, MCI nonamnestic-single
domain, MCI nonamnestic-multiple domain, and dementia. Any participant found to be
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demented at baseline or to have become demented at 12 or 24 months follow-up was
removed from the study and offered open treatment with donepezil.
We tested for APOE alleles (co-investigator MIK) using a previously published method.28
These data were available in 102 of 130 randomized subjects. We examined the association
between APOE*4 carrier status and MCI and with donepezil effects on cognition and mood.
Assessment and Primary Outcome Measures
Primary outcome measures were (a) a global measure of neuropsychological functioning, (b)
a composite measure of cognitive instrumental activities of daily living, and (c) recurrence
of major depression.
Neuropsychological functioning was assessed with 17 well established and validated
individual tests measuring multiple domains (Table 1). We transformed raw scores for
individual tests into Z-scores using the baseline distribution of a non-depressed, cognitively
normal, older-adult comparison group (n = 36) of similar age, education and medical health
recruited concurrently with the depressed participants. These Z-scores were averaged within
each neuropsychological area to produce domain scores and then averaged over all 17 tests
to calculate a global performance score. .
We explored the effect of donepezil and placebo on five domains of neuropsychological
functioning; speed of information processing, executive functioning, delayed memory,
language, and visuo-spatial function. The component tests of each domain are presented in
Table 1 and are the same as those previously reported by Butters et al.,29 with the exception
that the modified Rey-Osterreith Figure Copy replaced Clock Drawing. We computed the
following Cronbach’s alpha coefficients for each domain: language (0.73), visuospatial
(0.67), memory (0.66), executive (0.73), and speed of information processing (0.79).
Instrumental Activities of Daily Living (IADL)—We administered the PASS self-
report measures of habit (“does do”) and the PASS criterion-referenced observational
measurement performed in subjects’ homes (“can do”).7, 26, 30 The PASS is a
performance-based assessment of 26 daily living activities involving functional mobility,
personal care, and instrumental activities having a cognitive (e.g., medication management)
or physical (e.g., changing bed linens) emphasis. A clinician rater observes patients perform
each task and rates them according to pre-determined criteria on a 4-point ordinal scale,
ranging from 0 (unable) to 3 (independent). Levels of assistance are rated on a 9-point
hierarchy consisting of three levels each of verbal, gestural, and physical assists. A
composite measure of thirteen cognitive IADL items included performance on activities
such as shopping (cash exchange), bill paying, medication management, and home safety.
Distribution of the cognitive IADL composite measures was dichotomous: participants
either had independent performance or they did not. We report the percentage of subjects at
each assessment point with independent functioning.
Recurrent Episodes of Major Depression—As in our previous maintenance therapy
trials 31, 32, recurrence of major depression was defined using SCID/DSM-IV criteria 22, a
Hamilton depression score (17-item)23 of 15 or higher over two consecutive weeks, and
confirmation by a geriatric psychiatrist not involved in the participant’s treatment.
Randomization and Masking
A computer-generated random assignment sequence using permuted blocks of 4 or 2
(depending on site) was stratified by site of recruitment (mental health specialty clinic
versus primary care), cognitive status (MCI present/absent), and use of rescue medication
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(SNRI, aripiprazole) during initial open treatment. The randomization list was prepared in
advance by our statistician (SM). Only the research pharmacist had access to the
randomization list. The blind was not broken until outcome analyses had been completed.
Neuropsychological function, cognitive IADL, and clinical status were evaluated by
independent assessors who were blind to participants’ randomized treatment assignment and
baseline cognitive status (MCI present/absent). Identical capsules of donepezil (5 mg, 10
mg) and placebo were provided gratis by Pfizer/Eisai.
Intervention
To qualify for randomization to donepezil or placebo, full antidepressant response was
required (defined as a Hamilton score of 10 or less for three consecutive weeks). Patients
initially received open antidepressant pharmacotherapy with escitalopram (up to 20 mg/day).
Those not responding fully were switched to a serotonin noradrenergic reuptake inhibitor
(SNRI: duloxetine, up to 120 mg/day), followed as needed by aripiprazole augmentation (up
to 15 md/day) to achieve full response. The goal of using this algorithm was to increase the
number of subjects available to participate in the maintenance phase of the trial, a
precondition of which was full response to initial antidepressant pharmacotherapy. The
distribution of antidepressant treatment regimens was similar in both maintenance
conditions, with over 80% of subjects receiving either escitalopram or rescue, second-line
pharmacotherapy using duloxetine. That is, the percentage of subjects receiving second-line
(“rescue”) pharmacotherapy did not differ between the two maintenance arms of the study.
The antidepressant regimen associated with full response was continued during maintenance
treatment, unless a subject experienced recurrence. To allow completion of the 2-year study,
we treated recurrences using higher doses or switching from escitalopram to SNRI. Most of
the recurrent episodes (24/28, 85.7%) were treated to response. We encouraged adherence to
antidepressant pharmacotherapy at each clinic visit to assure maximal benefit. We tracked
adherence by asking what percentage of their doses subjects had taken since the last clinic
visit.
Sixty-seven subjects were randomized to donepezil and 63 to placebo. The mean (SD) dose
of donepezil at study exit was 7.8 (2.5) mg/daily (mostly AM dosing), with 37/67 donepezil
subjects on 10 mg daily and 30 on 5 mg daily (they were unable to tolerate a full dose due
mainly to GI side effects and vivid dreams or other sleep disturbances).
Statistical Analyses
We followed the intention-to-treat principle: all randomized participants and all follow-up
assessments were considered in the analyses. Analyses were performed by study statisticians
in the Graduate School of Public Health (SJA, SM) and in the Department of Psychiatry
(PRH, AEB). The study sponsors played no role in the outcomes analysis.
Primary Analysis: Donepezil Effects on Cognition and Depression Recurrence in the
Combined Group of Cognitively Normal and Mildly Cognitively Impaired Participants
The primary analysis of changes in outcome measures over two years was a repeated-
measures mixed effects model with both treatment and time as main fixed effects. To control
for baseline cognitive classification, MCI classification was entered as a covariate along
with all two-way interactions and the three-way interaction. In the analysis of the
neuropsychological measures, we used the PROC Mixed procedure. In the analysis of the
dichotomized PASS data (independent verses assisted performance), we used a logistic link
function in the PROC GLIMMIX procedure. All statistical analyses were conducted using
the SAS version 9.2.
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We used Kaplan-Meier (KM) curves to quantify the percentage of participants who were
free of depression recurrence over time 33. Cox proportional hazard (PH) models quantified
hazard ratios (HR) comparing the two treatment groups. Tests of proportionality were
conducted via the method proposed by Grambsch and Therneau 34 and, in all cases,
indicated that proportionality assumptions were valid. Formal tests of treatment by MCI
interaction and treatment effectiveness for MCI and cognitively normal participants were
conducted using Cox PH models.
To adjust for participants who had permanently dropped out of the study, we classified
terminations as being due either to study design (for example, adjudication of dementia) or
to any other type of termination (for example, adverse events). We compared the temporal
patterns of termination status by treatment arm for each type of termination, by examining
cumulative incidence curves which adjusted for the competing causes of termination 35. All
intermittent missing values were considered missing at random (MAR).
No significant treatment difference for terminations by study design was observed; however
a significant treatment effect for all other terminations was noted (p = .03). Treatment
difference in termination not by study design was found mostly in subjects with MCI.
Consequently, we conditioned on MCI status in the mixed effect model to account for this
covariate-dependent missingness mechanism for both neuropsychological functioning and
cognitive instrumental activities of daily living.
Post-hoc Analysis: Donepezil Effects on Subgroups of Cognitively Normal and Mildly
Cognitively Impaired Participants
We used the Fisher exact test to compare rates of dementia conversion and depression
recurrence in subgroups of cognitively normal (n = 73) and mildly cognitively impaired (n =
57) subjects, while under randomized maintenance treatment with donepezil or placebo
augmentation of maintenance antidepressant pharmacotherapy.
RESULTS
A. Primary Analyses
As shown in Table 1, donepezil subjects did not differ from those on placebo in age, gender,
race, years of education, depression scores at baseline and randomization, medical burden
(Cumulative Illness Rating Scale)36, cognitive status (Mini-Mental Status Exam)37, or
baseline Z-scores for global cognition and each of the five domain scores. The distribution
of ADRC diagnoses (normal cognition, subtypes of Mild Cognitive Impairment) also did not
differ. The types of antidepressant pharmacotherapy were similar in the two treatment arms.
Neuropsychological performance (Table 2, Figure 2)—The groups changed at
different rates over time, with the donepezil group showing a temporary advantage in global
cognition at one year that was not sustained at two years (treatment x time interaction F =
3.78, df = 2, 126 p = 0.03). However, group difference effect sizes were small at one year
(Cohen’s d = 0.27) and at two years (Cohen’s d < 0.05) and not statistically significant. As
shown in Table 2 and Figure 2, two domains of cognitive functioning demonstrated
treatment by time interaction: executive function (F = 6.93; DF = 2,126; p = 0.001) and
memory (F = 3.93; DF = 2,123; p = 0.02). In addition, language demonstrated a higher-order
interaction of treatment, time, and MCI status (F = 3.14; DF = 2,126, p = 0.05)
Instrumental activities of daily living with a cognitive emphasis (C-IADL)—
Performance on cognitive IADL tasks showed a marginally different pattern of change over
time in subjects receiving donepezil vs. placebo (treatment x time interaction F = 2.94, df =
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2, 137, p = 0.06). The percentage of subjects on donepezil reporting independent task
performance at 12 months (Cohen’s d = 0.20, p = 0.27) and at 24 months (d=0.29, p = 0.11)
did not differ from placebo. We did not detect differential effects of donepezil over time on
task performance observed in subjects’ homes (treatment x time interaction F = 0.93, df = 2,
136, p = .40).
Recurrence of major depressive episodes (Figure 3)—The recurrence percentages
by two years were 35% [95% CI: 24%, 46%] on donepezil and 19% [95% CI: 9%, 29%] on
placebo (log rank chi squared = 3.97, p = .05; HR = 2.09 [95% CI: 1.00, 4.41].
B. Post-Hoc Analyses of Dementia Conversion and Depression Recurrence in Cognitively
Normal and Mildly Cognitively Impaired Subgroups
Thirteen of all 130 subjects (10%) converted to dementia over two years: 1 who had been
cognitively normal at the start of maintenance treatment and the remaining 12 who had had
Mild Cognitive Impairment. Thus, 12/57, or 21.1% of the subgroup with MCI, converted to
dementia: 3/30 (10%; 95% CI: 0, 21) on donepezil and 9/27 (33%; 95% CI: 16%, 51%) on
placebo; Fisher exact p = .05. There was a trend for APOE*4 carriers to be over-represented
among those with MCI at baseline (12/43) versus those with normal cognition (8/59): Fisher
exact p = 0.08. With respect to types of dementia adjudicated by the ADRC, 8/12 had AD
probable, two had AD possible, one had fronto-temporal dementia, and one ‘dementia/
other.” Five of 11 MCI subjects with APOE data were APOE*4 carriers (one 2/4, four 3/4).
In the subgroup with normal cognition at the start of maintenance treatment (n =73), 6/37
(16.2%) on donepezil experienced cognitive decline (that is, five developed MCI and one,
dementia), and 8/36 (22.2%) on placebo showed cognitive decline (all MCI) (Fisher exact
p=0.56). In contrast to those showing cognitive decline, 7 of the 57 with MCI at the start of
maintenance treatment were adjudicated to have reverted to normal cognition on follow-up
In the MCI subgroup, 8/30 on donepezil had recurrence of major depression over two years
versus 3/27 on placebo: 44% [95% CI: 28%, 60%] versus 12% [95% CI: 1%, 23%] (log
rank chi squared = 4.91, p = .03). See figure 3. In the cognitively normal subgroup, 11/37 on
donepezil had recurrence versus 8/36 on placebo: NS. Recurrence was not significantly
affected by dose of donepezil (5 mg versus 10 mg) (LR = 0.43, p = .51). Two subjects on
donepezil developed mania (in the absence of a history of bipolar spectrum disorders), and a
third subject (with a history of suicidal ideation) attempted suicide by overdose. (See Figure
1 for summary of adverse events associated with donepezil and placebo.)
In further exploratory analyses, we observed a trend for a greater proportion of those who
experienced recurrence to have received second-line or rescue antidepressant
pharmacotherapy (with SNRI, aripiprazole) following only partial response to escitalopram
during phase 1. Specifically, 17/30 who experienced recurrence (56.7%) versus 38/100 who
did not experience recurrence (38%) received second-line pharmacotherapy (Fisher exact p
= 0.09). However, the proportion receiving rescue pharmacotherapy did not differ between
those randomized to donepezil (29/67) and placebo (26/63): Fisher exact p = 0.86 (thus
suggesting that recurrence was related to the use of donepezil and not to depression
treatment refractoriness). Sally, please highlight in yellow the information contained in
parentheses in the preceding sentence The two groups (recurrence yes/no) did not differ in
the distribution of APOE alleles (Fisher exact p = 0.21); 19% of both those with recurrence
(5/26) and those without (15/76) were APOE*4 carriers. Amnestic and non-amnestic MCI
subjects also did not differ in the proportion experiencing recurrence of major depression:
6/35 and 5/22, respectively (Fisher exact p=.73). Of the 30 participants who experienced
recurrence, 24 of 28 (85.7%) were treated to response (Hamilton Depression Rating Scale
score of 10 or less over three consecutive weeks).
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CONCLUSIONS
This is the first confirmatory RCT of ChEI augmentation in older non-demented adults with
a recent major depressive episode. Our primary analyses indicated a temporary positive
effects of donepezil on global cognitive function (as well as on domain-specific measures of
executive function and memory), marginal effects on a composite measure of cognitive
instrumental activities of daily living, and, in a post-hoc subgroup analysis of those with
MCI, a lower rate of conversion to dementia over two years (33% on placebo versus 10% on
donepezil). However, co-administration of donepezil also led to higher rates of recurrent
depressive episodes (35% versus 19% in the entire group of participants; and 45% versus
12% in the MCI subgroup), despite the use of maintenance antidepressant pharmacotherapy.
The clinical significance of increased affective episodes is not only the suffering and
morbidity associated with each depressive episode, but also the risk for chronicity, with each
recurrent episode becoming more difficult to treat to full remission 38.
Post-hoc analyses suggested that for cognitively intact patients after remission of depression,
the addition of donepezil to maintenance antidepressant pharmacotherapy appeared to have
no clear benefit: it did not prevent relapse nor progression to MCI/dementia over two years.
In those with MCI after remission of depression, the addition of donepezil to maintenance
antidepressant pharmacotherapy appeared to prevent progression to dementia over two years
but also to increase recurrence of depression. We caution, however, that these observations
are based upon post-hoc subgroup analyses. The study may have been underpowered to
detect a potential benefit in cognitively normal subjects. These observations are, therefore,
preliminary and in need of confirmation by other studies that are designed and powered to
confirm them.
There are two published, short-term pilot studies of ChEI augmentation of antidepressant
treatment of non-demented older patients with major depression and cognitive impairment
39, 40. In a 12-week, randomized, double-blind, placebo-controlled study of 23 adults older
than age 50, Pelton et al 39, reported that donepezil was associated with greater improvement
in memory (immediate recall) than those on placebo. In a 24-week double-blind, placebo-
controlled pilot study of 38 non-demented depressed adults older than 50, Holtzheimer et al.
40 observed no significant differences in measures of mood or cognition over the study 24
weeks, but did report high dropout among galantamine-randomized subjects.
While some treatment studies with ChEIs in non-demented persons with MCI have shown
benefit in cognitive performance and rates of conversion to dementia 6, 7, others have not,
for example.41, 42 The Cochrane review of donepezil in MCI concluded that the benefits of
ChEIs are minor, short-lived, and associated with significant side effects 13. Of interest, and
consistent with our findings of a lower, slower conversion rate to dementia associated with
donepezil use in MCI patients, Lu et al. study (2009)7 of 726 subjects with amnestic MCI
randomized to donepezil, vitamin E, or placebo also found that depressive symptoms were
predictive of progression from MCI to Alzheimer’s Disease over three years but that
donepezil slowed progression to Alzheimer’s Disease relative to placebo and vitamin E. Lu
et al. found that donepezil was not associated with improvement in depressive symptoms. In
contrast to our study, the authors excluded subjects with episodes of major depression
occurring in the previous two years, whereas we required subjects to have a current episode.
Our data appear to be consistent with those of Lu et al in suggesting a lower dementia
conversion rate on donepezil in MCI subjects with a history of depression. Although our
data to not allow us to say whether subjects with a history of depression (as distinct from a
recent episode) are at higher risk for recurrence on donepezil, such subjects should be
watched carefully if placed on donepezil.
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The current study differs in several respects from previously reported cholinesterase
inhibitor (ChEI) trials conducted in patients with MCI: 41-44 (1) we examined older adults
with major depression, a population excluded from ChEI trials, but one which is relevant to
psychiatric practice with complicated older patients; (2) our study thus expands the evidence
base available to treat patients that have been excluded from trials sponsored by industry and
by the Alzheimer Disease Cooperative Study (ADCS) group; and (3) our study examined a
more heterogeneous group of MCI subjects, including those with non-amnestic and multiple
cognitive domain forms as well as the amnestic forms included in industry-sponsored and
ADCS trials. Until now there has been no evidence to guide psychiatric treatment of these
complicated older adults with major depression and the full spectrum of MCI.
Furthermore, in contrast to ChEI trials in dementia, where improvements in neuropsychiatric
symptoms have been noted 15, 16, we detected a clinically significant increase in recurrent
episodes of major depression. This observation may be consistent with the cholinergic
hypothesis of mood disorders 19, 20, which holds that persons with depression show
cholinergic hypersensitivity to depressogenic effects of cholinoceptive agents. The
observation is also consistent with a recent report of scopolamine’s antidepressant efficacy
in major depressive disorder.21 Such episodes may further amplify cognitive impairment and
associated disability, thus offsetting the temporary gains in cognition observed earlier on.
The positive effects of donepezil--modest cognitive and functional enhancement and
slowing of dementia conversion rate-- must be weighed against the risk of recurrence of
major depression in those with mild cognitive impairment and possible appearance of manic
symptoms and worsening of suicidal ideation or behavior.
Unstructured Abstract (requested by Editor)
Cognitive impairment in late-life depression is a core feature of the illness. We tested
whether the combination of donepezil and antidepressant pharmacotherapy (n=67) is
superior to placebo + antidepressant pharmacotherapy (n=63) in improving cognition and
in reducing recurrences of major depression over two years of maintenance treatment.
We observed that combination donepezil + antidepressant modestly improved global
cognition (including executive function, language, memory) and cognitive IADL.
However, donepezil-treated patients were also more likely to experience recurrent
episodes of major depression: 35% versus 19% (log rank chi squared = 3.97, p=.05).
In post-hoc analyses, we observed that of 57 participants with Mild Cognitive
Impairment, three of 30 on donepezil (10%; 95% CI: 0, 21) and nine of 27 (33%; 95%
CI: 16, 51) on placebo converted to dementia (primarily Alzheimer’s) over two years
(Fishers exact p = 0.05). However, the MCI subgroup also had a 44% recurrence rate on
donepezil versus 12% on placebo (LR = 4.91, p = .03).
The cognitively normal subgroup (n = 73) showed no cognitive benefit or change in
depression recurrence on donepezil.
The use of donepezil as augmentation treatment of late-life depression depends upon a
careful weighing of risks and benefits in those with MCI, while no apparent benefit
accrues in those with normal cognition.
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Figure 1.
Consort Flow Chart of Participants with Depression.
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Figure 2.
Donepezil + antidepressant temporarily improved global cognition relative to placebo +
antidepressant (treatment x time interaction F = 3.78, df = 2,126, p = .03). Within specific
domains, a similar treatment x time interaction was seen for executive functioning and
memory. A higher-order three-way interaction was observed for language (MCI x treatment
x time). Please see table 2 for mixed effects modeling results. Table 1 lists the specific
neuropsychological tests that were used to compute a composite measure of global cognitive
function as well as domain-specific measures
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Figure 3.
The rate of recurrent major depression was 35% on donepezil versus 19% on placebo
(LR=3.97, p=.05; number needed to harm [NNH=6.2]). Subjects with MCI had a 44%
recurrence rate on donepezil versus 12% on placebo (LR=4.91, p=.03; number need to harm
[NNH]=3.2). In subjects with normal cognition, recurrence rates did not differ on donepezil
and placebo. The hazard ratio for recurrence was 4.02 (95% CI: 1.06, 15.19) in MCI
subjects versus 1.49 (0.60, 3.71) in subjects with normal cognition.
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Table 1
Descriptive Data N=130 Depressed
ALL
Depressed
N=130
Donepezil
N=67
Placebo
N=63
Age 73.5 (6.2) 73.1 (6.5) 73.9 (5.8)
Gender F=100 F=49 F=51
M=30 M=18 M=12
Education (years) 13.6 (2.5) 13.6 (2.5) 13.6 (2.6)
1Hamilton Depression Rating Scale
@ Baseline
18.7 (3.3) 18.7 (3.3) 18.8 (3.4)
Hamilton Depression Rating Scale @
randomization
6.6 (3.2) 7.0 (3.3) 6.3 (3.1)
2Cumulative Illness Rating (CIRS-G)
Total 10.5 (3.3) 10.5 (3.1) 10.5 (3.5)
Count 6.2 (1.9) 6.2 (2.0) 6.3 (2.0)
3Mini-Mental State Examination
(MMSE)
28.5 (1.4) 28.5 (1.4) 28.4 (1.4)
ADRC DIAGNOSIS @
randomization
No cognitive disorder 73 37 36
MCI 57 30 27
MCI amnestic, multiple domain 14 16
MCI non-amnestic, multiple domain 8 4
MCI non-amnestic, single domain 7 4
MCI amnestic, single domain 1 3
4 Neuropsychological Baseline Z-
scores, global cognition
−0.47 (0.88) −0.47 (.76)
Information Processing Speed −0.88 (1.40) −0.74 (1.36)
Visuospatial Domain −0.24 (0.74) −0.33 (0.80)
Language Domain −0.42 (0.97) −0.45 (0.82)
Memory Domain −0.28 (0.92) −0.38 (0.94)
Executive Domain −0.55 (1.40) −0.53 (1.50)
PASS Independence
C-IADL Observed Independence %
(n)
54.1 (33/61) 61.8 (34/55)
C-IADL Self-report : Independence
% (n)
48.3 (29/60) 60.0 (33/55)
Information Processing Speed: Trail Making Test A (Reitan & Wolfson, 1993), Digit Symbol Subtest (Wechsler, 1996), Grooved Pegboard
(Matthews & Klove, 1964
Visuospatial Function: Modified Rey-Osterreith Figure Copy (Osterreith, 1944; Rey, 1941), Simple Drawings (Goodglass & Kaplan, 1983), Block
Design (Wechsler, 1996)
Language Function: Boston Naming Test (Goodlass & Kaplan, 1983), Spot-the-Word (Baddeley et al., 1992), Letter Fluency (Borkowski et al.,
1967), Animal Fluency (Borkowski et al., 1967)
Delayed Memory: Logical Memory Delayed Recall (Wechsler, 1997), Modified Rey-Osterreith Figure Delayed Recall (Osterreith, 1944; Rey,
1941), California Verbal Learning Test Delayed Recall (Delis, 1987)
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Executive Function: Stroop Neuropsychological Screening Test (Trenerry et al. 1989), Executive Interview (Royall et al., 1992), Trails Making
Test B/A Ratio (Reitan & Wolfson, 1993), Wisconsin Card Sorting Test errors (Berg, 1948)
1
Scores for the 17-item Hamilton Rating Scale for Depression range from O-52, with higher scores indicating more severe depression.
2
Scores for the Cumulative Illness Rating Scale for Geriatrics range from 0-52, with higher scores indicating worse health status.
3
Scores for the Mini-mental State Examination range from 0-30, with higher scores indicating better mental status.
4
Specific tests constituting our global cognitive factor (Figure 2) listed by conceptual domain
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Table 2
Mixed Effects Models of Neuropsychological Performance Over Two Years
A. Global Cognition
Effect NumDF
Den
DF F Value Pr > F
TREATMENT 1 126 0.34 0.5614
MCI 1 126 86.31 <.0001
TIME 2 126 6.36 0.0023
TREATMENT*TIME 2 126 3.78 0.0256
TIME*MCI 2 126 2.78 0.0659
TREATMENT*MCI 1 126 0.07 0.7970
TREATME*TIME*MCI 2 126 0.53 0.5900
B. Informational Processing Speed Domain
Effect NumDF
Den
DF F Value Pr > F
TREATMENT 1 124 0.06 0.8043
MCI 1 124 34.44 <.0001
TIME 2 124 5.84 0.0038
TREATMENT*TIME 2 124 2.43 0.0923
TIME*MCI 2 124 0.63 0.5354
TREATMENT*MCI 1 124 0.59 0.4457
TREATME*TIME*MCI 2 124 1.78 0.1732
C. Visuospatial Domain
Effect NumDF
Den
DF F Value Pr > F
TREATMENT 1 126 1.88 0.1730
MCI 1 126 12.86 0.0005
TIME 2 126 13.36 <.0001
TREATMENT*TIME 2 126 1.33 0.2694
TIME*MCI 2 126 0.42 0.6594
TREATMENT*MCI 1 126 0.09 0.7623
TREATME*TIME*MCI 2 126 0.08 0.9239
D. Language Domain
Effect NumDF
Den
DF F Value Pr > F
TREATMENT 1 126 0.58 0.4485
MCI 1 126 43.68 <.0001
TIME 2 126 2.19 0.1156
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D. Language Domain
Effect NumDF
Den
DF F Value Pr > F
TREATMENT*TIME 2 126 0.82 0.4443
TIME*MCI 2 126 0.95 0.3884
TREATMENT*MCI 1 126 0.29 0.5886
TREATME*TIME*MCI 2 126 3.14 0.0469
E. Memory Domain
Effect NumDF
Den
DF F Value Pr > F
TREATMENT 1 126 5.59 0.0196
MCI 1 126 94.56 <.0001
TIME 2 126 0.85 0.4315
TREATMENT*TIME 2 126 3.93 0.0221
TIME*MCI 2 126 0.42 0.6570
TREATMENT*MCI 1 126 2.91 0.0902
TREATME*TIME*MCI 2 126 1.19 0.3089
F. Executive Domain
Effect NumDF
Den
DF F Value Pr > F
TREATMENT 1 126 0.10 0.7517
MCI 1 126 45.99 <.0001
TIME 2 126 2.35 0.0994
TREATMENT*TIME 2 126 6.93 0.0014
TIME*MCI 2 126 4.14 0.0182
TREATMENT*MCI 1 126 0.92 0.3387
TREATME*TIME*MCI 2 126 2.00 0.1396
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